There continues to be steady demand for lab space in biotech hubs across the country creating a huge opportunity for development, said Alan Gold, CEO of BioMed Realty Trust. Gold added that biotech M&A is positive for lab space developers like BioMed because it brings capital back into the industry. He said BioMed has about 60% of its space tied to biotech with the remainder occupied by Big Pharma companies and Universities. Nevertheless, Gold said BioMed is not overly leveraged to the booming biotech market. Finally, Gold said he expects to raise the dividend as earnings increase.
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
